The fight against rare cancers faces myriad challenges, including missed or wrong
diagnoses, lack of information and diagnostic tools, too few samples and too little funding …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Fibrolamellar hepatocellular carcinoma (FLC) is a usually lethal primary liver cancer driven
by a somatic dysregulation of protein kinase A. We show that the proteome of FLC tumors is …

Hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC) are rare primary
malignant liver cancers in children and young adults. HB is the most common and accounts …

Fibrolamellar carcinoma (FLC) of the liver is a rare type of liver cancer that is prevalent in
children and young adults, often less than 40 years old. The etiology is unclear. It presents …

Liver tumors account for approximately 1%–2% of all pediatric malignancies, with the two
most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC) …

Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer caused by a dominant
recurrent fusion of the heat shock protein (DNAJB1) and the catalytic subunit of protein …

The DNAJB1-PRKACA fusion transcript was identified as the oncogenic driver of tumor
pathogenesis in fibrolamellar hepatocellular carcinoma (FL-HCC), also known as …

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a very rare liver cancer
(incidence±0.02/100,000, 1% HCC) that mostly affects adolescents and young adults …

蛋白质的非正常表达往往会直接或间接导致癌症的发生. 目前, 靶向特定蛋白质的小分子抑制剂
在肿瘤治疗领域中得到了广泛使用. 然而, 小分子抑制剂存在易使机体产生耐药性 …